SymBio Pharmaceuticals Limited (TYO:4582)
Japan
· Delayed Price · Currency is JPY 92.00
0.00 (0.00%)
Apr 28, 2026, 3:30 PM JST
SymBio Pharmaceuticals Cash Flow Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -4,748 | -3,806 | -1,195 | 2,106 | 2,032 | Upgrade
|
| Depreciation & Amortization | - | - | 98 | 99 | 93.96 | Upgrade
|
| Other Amortization | - | - | - | - | 1.95 | Upgrade
|
| Loss (Gain) From Sale of Assets | 109 | 131 | 568 | - | 0.69 | Upgrade
|
| Stock-Based Compensation | - | - | - | - | 124.27 | Upgrade
|
| Other Operating Activities | 2 | 27 | -377 | -420 | -1,048 | Upgrade
|
| Change in Accounts Receivable | 163 | 489 | 1,171 | 62 | -1,741 | Upgrade
|
| Change in Inventory | -50 | 54 | 237 | -82 | 559.24 | Upgrade
|
| Change in Accounts Payable | -169 | -215 | -356 | 662 | -595.78 | Upgrade
|
| Change in Other Net Operating Assets | 118 | -96 | -340 | -813 | 711.88 | Upgrade
|
| Operating Cash Flow | -4,575 | -3,416 | -194 | 1,614 | 140.04 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | 1052.51% | - | Upgrade
|
| Capital Expenditures | - | -19 | -204 | -2 | -25.45 | Upgrade
|
| Sale (Purchase) of Intangibles | -82 | -27 | -28 | -45 | -38.38 | Upgrade
|
| Other Investing Activities | 7 | 43 | -144 | - | -7.01 | Upgrade
|
| Investing Cash Flow | -75 | -3 | -376 | -47 | -70.85 | Upgrade
|
| Long-Term Debt Issued | 2,924 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -552 | - | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | 2,372 | - | - | - | - | Upgrade
|
| Issuance of Common Stock | 1,249 | 709 | 681 | 630 | 0.9 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -2 | -68.83 | Upgrade
|
| Other Financing Activities | - | -1 | -1 | -1 | -4 | Upgrade
|
| Financing Cash Flow | 3,621 | 708 | 680 | 627 | -71.92 | Upgrade
|
| Foreign Exchange Rate Adjustments | -50 | 158 | 125 | 213 | 14.21 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -1 | - | -1 | 14 | - | Upgrade
|
| Net Cash Flow | -1,080 | -2,553 | 234 | 2,421 | 11.48 | Upgrade
|
| Free Cash Flow | -4,575 | -3,435 | -398 | 1,612 | 114.59 | Upgrade
|
| Free Cash Flow Growth | - | - | - | 1306.78% | - | Upgrade
|
| Free Cash Flow Margin | -350.04% | -140.09% | -7.12% | 16.11% | 1.39% | Upgrade
|
| Free Cash Flow Per Share | -91.11 | -76.17 | -9.97 | 40.70 | 2.95 | Upgrade
|
| Cash Interest Paid | 39 | - | - | - | - | Upgrade
|
| Cash Income Tax Paid | 12 | -39 | 354 | 363 | 3.8 | Upgrade
|
| Levered Free Cash Flow | -3,089 | -2,055 | -143.5 | 1,542 | -226.95 | Upgrade
|
| Unlevered Free Cash Flow | -2,996 | -2,055 | -143.5 | 1,542 | -226.95 | Upgrade
|
| Change in Working Capital | 62 | 232 | 712 | -171 | -1,065 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.